Skip to main content
Erschienen in: Journal of Translational Medicine 1/2022

Open Access 01.12.2022 | Retraction Note

Retraction Note: Molecular analysis of the effects of Piroxicam and Cisplatin on mesothelioma cells growth and viability

verfasst von: Alessandra Verdina, Irene Cardillo, Angela Nebbioso, Rossella Galati, Simona Menegozzo, Lucia Altucci, Ada Sacchi, Alfonso Baldi

Erschienen in: Journal of Translational Medicine | Ausgabe 1/2022

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN
Hinweise
The original article can be found online at https://​doi.​org/​10.​1186/​1479-5876-6-27.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Retraction: Journal of Translational Medicine 2008, 6:27 https://doi.org/10.1186/1479-5876-6-27
The Editor-in-Chief has retracted this article [1]. After publication, concerns were raised regarding potential issues in the western blot images presented in the figures. Specifically:
  • Two pairs of bands appear highly similar in Fig. 5a—MSTO C CycD1 (CTRL 3 h and 6 h) and P + C Actin (CTRL 6 h and 24 h).
  • A number of bands appear highly similar in Fig. 6b P + C Actin.
  • Also in Fig. 6b, NCI P p21 bands (CTRL 6 h and 24 h) appear highly similar to P + C p21 bands (CTRL 3 h and 6 h).
  • All NCI Actin bands appear to be highly similar in Figs. 5a and 6b.
  • NCI C Actin bands in Figs. 5a and 6b appear to be highly similar but rotated 180 degrees, with the same bands representing different groups.
  • In Fig. 6b NCI blots, some backgrounds appear inconsistent and contain unexpected breaks or changes between bands.
As the article was published in 2008, the authors are unable to provide the raw data used to produce these figures. The Editor-in-Chief therefore no longer has confidence in the presented data.
Alfonso Baldi does not agree to this retraction. Angela Nebbioso and Lucia Altucci have not explicitly stated whether they agree to this retraction. Simona Menegozzo has not responded to any correspondence from the editor or publisher about this retraction. The Publisher has not been able to obtain a current email address for author Alessandra Verdina, Irene Cardillo, Rossella Galati and Ada Sacchi.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
download
DOWNLOAD
print
DRUCKEN
Metadaten
Titel
Retraction Note: Molecular analysis of the effects of Piroxicam and Cisplatin on mesothelioma cells growth and viability
verfasst von
Alessandra Verdina
Irene Cardillo
Angela Nebbioso
Rossella Galati
Simona Menegozzo
Lucia Altucci
Ada Sacchi
Alfonso Baldi
Publikationsdatum
01.12.2022
Verlag
BioMed Central
Erschienen in
Journal of Translational Medicine / Ausgabe 1/2022
Elektronische ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-022-03834-5

Weitere Artikel der Ausgabe 1/2022

Journal of Translational Medicine 1/2022 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.